National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-11: The Prospects for Immunizing Against Rabies Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
297
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

From among these various vaccine strategies the committee chose to evaluate three candidates that it felt were technically feasible within a decade and were representative of fundamentally different strategies. The three candidates selected were a vero cell derived vaccine, a glycoprotein based vaccine, and a vector vaccine approach.

REFERENCES

Acha, P.N. 1981. A review of rabies prevention and control in the Americas, 1970–1980. Overall status of rabies. Bull. Off. Int. Epiz. 93(1–2):9–52.

American Public Health Association. 1985. Rabies. Pp. 310–318 in Control of Communicable Diseases in Man, A.S.Benenson, ed. Washington, D.C.: American Public Health Association.


Barth, R., H.Gruschkau, U.Bijok, J.Hilfenhaus, J.Hinz, L.Mikke, H.Moser, O.Jaeger, H.Ronneberger, and E.Weinmann. 1984. A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PECE-vaccine by laboratory tests. J. Biol. Stand. 12:29–46.


Keller, H., A.Gluck, A.Wegmann, and A.I.Wandeler. 1984. Immunogenicity of a new, highly purified and concentrated duck embryo rabies vaccine. Schweiz. Med. Wschr. 114:648–653.

Koprowski, H., K.J.Reagan, R.I.McFarlan, B.Dietzschold, and T.J. Wiktor. 1985. New generation of rabies vaccines: Rabies glycoprotein gene recombinants, anti-idiotypic antibodies and synthetic peptides. Pp. 151–156 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A.Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.


Lathe, R., M.-P.Kieny, J.-P.Lecocq, P.Drillien, T.J.Wiktor, and H. Koprowski. 1985. Immunization against rabies using a vaccinia-rabies recombinant virus expressing surface glycoprotein. Pp. 157–162 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A. Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.


Malek, L.T., G.Soostmeyer, R.T.Garvin, and E.James. 1984. The rabies glycoprotein gene is expressed in Escherichia coli as a denatured polypeptide. Pp. 203–208 in Modern Approaches to Vaccines, R.M.Chanock and R.A.Lerner, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.


Population Reference Bureau. 1984. 1984 World Population Data Sheet. Washington, D.C.: Population Reference Bureau.


Rubin, R.H., J.Black, and G.R.Sharpless. 1969. Rabies in citizens of the United States. 1963–1968: Epidemiology, treatment, and complications of treatment. J. Infect. Dis. 120:268–273.


Schneider, L.G., and K.Bögel. 1983. The current global situation of human and canine rabies and its control. Paper presented at the Third Inter-American Meeting, at the Ministerial Level, on Animal Health, Washington, D.C., April 11–14, 1983.

Page
297
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)